Brief: Icecure Medical Receives FDA Response To De Novo Classification Request For Breast Cancer Study
20/09/2023 12:09
Sept 20 (Reuters) - Icecure Medical Ltd ICCM.O :
* ICECURE MEDICAL RECEIVES FDA RESPONSE TO DE NOVO
CLASSIFICATION
REQUEST FOR BREAST CANCER
* ICECURE MEDICAL LTD - CONTINUES ITS ICE3 CLINICAL STUDY,
LARGEST
CLINICAL TRIAL OF ITS KIND, WHICH IS EXPECTED TO COMPLETE DURING
Q1 OF 2024
Source text for Eikon: ID:nPn5BZcVma
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM